| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 41 | 2024 | 6915 | 2.100 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 23 | 2024 | 923 | 1.670 |
Why?
|
| Myelodysplastic Syndromes | 21 | 2024 | 2979 | 1.560 |
Why?
|
| Sulfonamides | 25 | 2024 | 1823 | 1.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 36 | 2024 | 15862 | 0.980 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 6 | 2024 | 426 | 0.840 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 11 | 2023 | 2527 | 0.840 |
Why?
|
| Azacitidine | 13 | 2024 | 1149 | 0.790 |
Why?
|
| Hematologic Neoplasms | 8 | 2019 | 1870 | 0.770 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2024 | 2796 | 0.720 |
Why?
|
| Cytarabine | 12 | 2022 | 1973 | 0.660 |
Why?
|
| Idarubicin | 6 | 2022 | 446 | 0.650 |
Why?
|
| Hydrazines | 3 | 2019 | 208 | 0.600 |
Why?
|
| Protein Kinase Inhibitors | 10 | 2023 | 4757 | 0.590 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 5 | 2023 | 505 | 0.530 |
Why?
|
| Pyrazoles | 7 | 2020 | 1471 | 0.500 |
Why?
|
| Antibodies, Bispecific | 3 | 2023 | 246 | 0.490 |
Why?
|
| Uridine | 2 | 2024 | 59 | 0.470 |
Why?
|
| Antineoplastic Agents | 14 | 2022 | 14289 | 0.460 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 482 | 0.420 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2012 | 45 | 0.410 |
Why?
|
| Aged | 51 | 2024 | 70117 | 0.410 |
Why?
|
| Middle Aged | 55 | 2024 | 86204 | 0.400 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2023 | 480 | 0.390 |
Why?
|
| Humans | 97 | 2024 | 261506 | 0.380 |
Why?
|
| Arabinonucleosides | 2 | 2017 | 437 | 0.370 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2021 | 801 | 0.370 |
Why?
|
| Fusion Proteins, bcr-abl | 7 | 2023 | 1094 | 0.360 |
Why?
|
| Dasatinib | 5 | 2023 | 862 | 0.360 |
Why?
|
| Aged, 80 and over | 30 | 2024 | 29902 | 0.350 |
Why?
|
| Adult | 45 | 2024 | 77950 | 0.340 |
Why?
|
| Pyrimidines | 8 | 2020 | 3518 | 0.330 |
Why?
|
| Hemophilia A | 1 | 2007 | 25 | 0.310 |
Why?
|
| Benzoates | 2 | 2019 | 136 | 0.310 |
Why?
|
| Remission Induction | 10 | 2023 | 3569 | 0.310 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2011 | 1546 | 0.300 |
Why?
|
| Factor VIII | 1 | 2007 | 75 | 0.300 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2022 | 3251 | 0.300 |
Why?
|
| Philadelphia Chromosome | 4 | 2022 | 793 | 0.290 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 1756 | 0.280 |
Why?
|
| Treatment Outcome | 24 | 2024 | 32848 | 0.280 |
Why?
|
| Male | 48 | 2024 | 123000 | 0.280 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 588 | 0.270 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2024 | 122 | 0.270 |
Why?
|
| Salvage Therapy | 5 | 2023 | 2054 | 0.270 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2019 | 305 | 0.260 |
Why?
|
| Aminoglycosides | 2 | 2022 | 220 | 0.260 |
Why?
|
| Female | 48 | 2024 | 141928 | 0.250 |
Why?
|
| Piperazines | 3 | 2010 | 2101 | 0.250 |
Why?
|
| Hearing Loss, Sudden | 1 | 2023 | 1 | 0.240 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 402 | 0.240 |
Why?
|
| Genes, ras | 1 | 2007 | 667 | 0.240 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2019 | 1299 | 0.240 |
Why?
|
| Mutation | 11 | 2023 | 15179 | 0.240 |
Why?
|
| Drug Delivery Systems | 2 | 2007 | 669 | 0.230 |
Why?
|
| Recurrence | 8 | 2024 | 4758 | 0.230 |
Why?
|
| Vincristine | 6 | 2022 | 1511 | 0.220 |
Why?
|
| Myeloproliferative Disorders | 2 | 2020 | 767 | 0.220 |
Why?
|
| Arsenicals | 1 | 2023 | 201 | 0.220 |
Why?
|
| Drug Combinations | 1 | 2024 | 621 | 0.210 |
Why?
|
| Mouth Mucosa | 1 | 2002 | 216 | 0.210 |
Why?
|
| Thrombocytosis | 1 | 2002 | 121 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2021 | 6207 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 10035 | 0.200 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2022 | 749 | 0.200 |
Why?
|
| Stomatitis | 1 | 2002 | 183 | 0.200 |
Why?
|
| Antimetabolites | 1 | 2021 | 69 | 0.200 |
Why?
|
| Carbazoles | 2 | 2014 | 87 | 0.200 |
Why?
|
| Blast Crisis | 2 | 2019 | 557 | 0.200 |
Why?
|
| Young Adult | 16 | 2024 | 21445 | 0.190 |
Why?
|
| Follow-Up Studies | 11 | 2023 | 14889 | 0.190 |
Why?
|
| Pyridazines | 1 | 2023 | 293 | 0.190 |
Why?
|
| Primary Myelofibrosis | 2 | 2019 | 831 | 0.190 |
Why?
|
| Vidarabine | 5 | 2022 | 1341 | 0.190 |
Why?
|
| Respiratory Insufficiency | 1 | 2024 | 330 | 0.190 |
Why?
|
| Prognosis | 15 | 2023 | 21713 | 0.190 |
Why?
|
| Disease-Free Survival | 9 | 2023 | 10001 | 0.190 |
Why?
|
| Daunorubicin | 2 | 2020 | 301 | 0.180 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2023 | 430 | 0.180 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2021 | 2390 | 0.180 |
Why?
|
| Drug Administration Schedule | 7 | 2020 | 3472 | 0.180 |
Why?
|
| Burkitt Lymphoma | 1 | 2022 | 335 | 0.170 |
Why?
|
| Neoplasm, Residual | 5 | 2024 | 1656 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 4 | 2022 | 4367 | 0.170 |
Why?
|
| Sulfones | 1 | 2020 | 143 | 0.170 |
Why?
|
| Polyethylene Glycols | 1 | 2002 | 615 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2023 | 5178 | 0.170 |
Why?
|
| Doxorubicin | 5 | 2020 | 3005 | 0.170 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2021 | 3552 | 0.170 |
Why?
|
| Carbolines | 1 | 2018 | 27 | 0.170 |
Why?
|
| Benzothiazoles | 2 | 2021 | 94 | 0.170 |
Why?
|
| Benzimidazoles | 2 | 2019 | 428 | 0.170 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 479 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 598 | 0.160 |
Why?
|
| Interferon-alpha | 1 | 2002 | 889 | 0.160 |
Why?
|
| Leukemia | 1 | 2007 | 1635 | 0.160 |
Why?
|
| Sepsis | 1 | 2024 | 652 | 0.160 |
Why?
|
| GRB2 Adaptor Protein | 1 | 2018 | 52 | 0.160 |
Why?
|
| Glycine | 1 | 2020 | 289 | 0.160 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 3230 | 0.160 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 184 | 0.160 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2018 | 119 | 0.160 |
Why?
|
| Survival Analysis | 7 | 2020 | 9180 | 0.150 |
Why?
|
| Core Binding Factors | 3 | 2022 | 112 | 0.150 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 1375 | 0.150 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2019 | 158 | 0.150 |
Why?
|
| Dexamethasone | 5 | 2020 | 1450 | 0.150 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2018 | 261 | 0.150 |
Why?
|
| Exotoxins | 1 | 2017 | 77 | 0.150 |
Why?
|
| Anemia, Aplastic | 1 | 2018 | 214 | 0.150 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 388 | 0.150 |
Why?
|
| Sirolimus | 2 | 2011 | 814 | 0.140 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2017 | 114 | 0.140 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 739 | 0.140 |
Why?
|
| Nuclear Proteins | 3 | 2023 | 3343 | 0.140 |
Why?
|
| Bacterial Toxins | 1 | 2017 | 228 | 0.130 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 846 | 0.130 |
Why?
|
| Phenylurea Compounds | 2 | 2021 | 580 | 0.130 |
Why?
|
| Cyclophosphamide | 5 | 2020 | 3001 | 0.130 |
Why?
|
| Imatinib Mesylate | 4 | 2019 | 1665 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 2 | 2021 | 1350 | 0.130 |
Why?
|
| Propensity Score | 3 | 2022 | 750 | 0.120 |
Why?
|
| Nitriles | 4 | 2020 | 906 | 0.120 |
Why?
|
| Furans | 1 | 2014 | 104 | 0.120 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 1046 | 0.120 |
Why?
|
| Adolescent | 10 | 2024 | 31252 | 0.110 |
Why?
|
| Ribonucleotide Reductases | 2 | 2003 | 51 | 0.110 |
Why?
|
| Immunophenotyping | 1 | 2017 | 1681 | 0.110 |
Why?
|
| Medical Records | 1 | 2014 | 415 | 0.110 |
Why?
|
| Niacinamide | 1 | 2014 | 421 | 0.110 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 2283 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2020 | 4938 | 0.110 |
Why?
|
| Neoplasms | 3 | 2023 | 15193 | 0.110 |
Why?
|
| Patient Safety | 1 | 2018 | 649 | 0.100 |
Why?
|
| Survival Rate | 6 | 2021 | 12221 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 1249 | 0.100 |
Why?
|
| Retrospective Studies | 9 | 2023 | 37905 | 0.100 |
Why?
|
| Risk | 3 | 2021 | 1972 | 0.100 |
Why?
|
| Clinical Trials as Topic | 3 | 2009 | 3719 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2018 | 2803 | 0.090 |
Why?
|
| Enzyme Inhibitors | 3 | 2020 | 1879 | 0.090 |
Why?
|
| Platelet Count | 2 | 2019 | 490 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 2195 | 0.090 |
Why?
|
| Benzamides | 3 | 2010 | 1832 | 0.090 |
Why?
|
| Hematinics | 1 | 2010 | 109 | 0.090 |
Why?
|
| Methotrexate | 2 | 2023 | 999 | 0.090 |
Why?
|
| Glucosides | 1 | 2008 | 64 | 0.080 |
Why?
|
| Cytogenetic Analysis | 2 | 2021 | 568 | 0.080 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2007 | 38 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 503 | 0.080 |
Why?
|
| Partial Thromboplastin Time | 1 | 2007 | 55 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 726 | 0.080 |
Why?
|
| Animals | 7 | 2012 | 59536 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2007 | 864 | 0.070 |
Why?
|
| Adenine | 2 | 2021 | 631 | 0.070 |
Why?
|
| Pemetrexed | 1 | 2007 | 102 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2007 | 79 | 0.070 |
Why?
|
| Glutamates | 1 | 2007 | 130 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2023 | 1493 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2022 | 12873 | 0.070 |
Why?
|
| Guanine | 1 | 2007 | 151 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2009 | 1391 | 0.070 |
Why?
|
| Bronchial Spasm | 1 | 2005 | 9 | 0.070 |
Why?
|
| Steroids | 1 | 2007 | 356 | 0.070 |
Why?
|
| Induction Chemotherapy | 2 | 2019 | 669 | 0.060 |
Why?
|
| Acute Disease | 2 | 2007 | 2422 | 0.060 |
Why?
|
| Anemia | 1 | 2010 | 689 | 0.060 |
Why?
|
| Piperidines | 2 | 2021 | 1035 | 0.060 |
Why?
|
| Rituximab | 2 | 2007 | 1528 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 1678 | 0.060 |
Why?
|
| Troponin I | 1 | 2005 | 127 | 0.060 |
Why?
|
| Signal Transduction | 4 | 2011 | 11965 | 0.060 |
Why?
|
| Thiosemicarbazones | 1 | 2003 | 23 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2007 | 576 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2020 | 665 | 0.060 |
Why?
|
| Leukemia, Lymphoid | 1 | 2003 | 276 | 0.060 |
Why?
|
| Oxides | 1 | 2023 | 211 | 0.060 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2023 | 170 | 0.050 |
Why?
|
| Fatigue | 2 | 2018 | 1239 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2007 | 717 | 0.050 |
Why?
|
| Splicing Factor U2AF | 1 | 2021 | 48 | 0.050 |
Why?
|
| Chromosome Aberrations | 2 | 2018 | 1960 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2023 | 324 | 0.050 |
Why?
|
| Spleen | 1 | 2023 | 676 | 0.050 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2021 | 88 | 0.050 |
Why?
|
| Safety | 2 | 2018 | 465 | 0.050 |
Why?
|
| Azoles | 1 | 2021 | 47 | 0.050 |
Why?
|
| Tretinoin | 1 | 2023 | 623 | 0.050 |
Why?
|
| Arthralgia | 1 | 2021 | 89 | 0.050 |
Why?
|
| Sarcoma | 1 | 2011 | 1725 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2007 | 3033 | 0.050 |
Why?
|
| Drug Evaluation | 1 | 2020 | 425 | 0.050 |
Why?
|
| Infection Control | 1 | 2002 | 270 | 0.050 |
Why?
|
| Cladribine | 1 | 2021 | 233 | 0.050 |
Why?
|
| Consolidation Chemotherapy | 1 | 2020 | 155 | 0.050 |
Why?
|
| Constipation | 1 | 2021 | 177 | 0.050 |
Why?
|
| IMP Dehydrogenase | 1 | 2020 | 27 | 0.050 |
Why?
|
| DNA Methylation | 2 | 2021 | 2669 | 0.050 |
Why?
|
| Maintenance Chemotherapy | 1 | 2021 | 202 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2022 | 668 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2022 | 9244 | 0.040 |
Why?
|
| Risk Factors | 3 | 2021 | 17523 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2018 | 87 | 0.040 |
Why?
|
| Heart | 1 | 2005 | 1223 | 0.040 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 65 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2021 | 6550 | 0.040 |
Why?
|
| Janus Kinase 1 | 1 | 2018 | 121 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2021 | 1290 | 0.040 |
Why?
|
| Skin | 1 | 2023 | 1259 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2019 | 486 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2023 | 984 | 0.040 |
Why?
|
| Imidazoles | 1 | 2023 | 999 | 0.040 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2017 | 53 | 0.040 |
Why?
|
| Exanthema | 1 | 2019 | 211 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 2927 | 0.040 |
Why?
|
| Disease Management | 1 | 2002 | 1052 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 409 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2020 | 1163 | 0.040 |
Why?
|
| Pyridines | 1 | 2003 | 1244 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 275 | 0.030 |
Why?
|
| Colitis | 1 | 2019 | 340 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2021 | 2232 | 0.030 |
Why?
|
| Phenotype | 1 | 2007 | 6295 | 0.030 |
Why?
|
| Pneumonia | 1 | 2021 | 751 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 1544 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2021 | 834 | 0.030 |
Why?
|
| Pedigree | 1 | 2019 | 1890 | 0.030 |
Why?
|
| Neutropenia | 1 | 2019 | 968 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 1048 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2023 | 2045 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2018 | 943 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 672 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2018 | 679 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2019 | 731 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2018 | 712 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2017 | 583 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 589 | 0.030 |
Why?
|
| Liver | 1 | 2023 | 2961 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 884 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 2315 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 719 | 0.030 |
Why?
|
| Obesity | 1 | 2023 | 2884 | 0.020 |
Why?
|
| Polypharmacy | 1 | 2010 | 57 | 0.020 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 10331 | 0.020 |
Why?
|
| Patient Selection | 1 | 2018 | 2055 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2002 | 2992 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2023 | 5270 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 4988 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 8865 | 0.020 |
Why?
|
| Genomics | 1 | 2020 | 2738 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 447 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 5047 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2022 | 3341 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2019 | 2638 | 0.020 |
Why?
|
| Disease Progression | 1 | 2019 | 6682 | 0.020 |
Why?
|
| Oncogene Proteins v-abl | 1 | 2007 | 5 | 0.020 |
Why?
|
| Genes, abl | 1 | 2007 | 110 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2007 | 84 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 2007 | 64 | 0.020 |
Why?
|
| Folic Acid Antagonists | 1 | 2007 | 45 | 0.020 |
Why?
|
| Nucleosides | 1 | 2007 | 60 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 6311 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2007 | 169 | 0.020 |
Why?
|
| Drugs, Investigational | 1 | 2007 | 135 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2007 | 290 | 0.020 |
Why?
|
| Microtubules | 1 | 2007 | 270 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2007 | 543 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2007 | 566 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 5539 | 0.020 |
Why?
|
| Drug Design | 1 | 2007 | 375 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2007 | 842 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2008 | 398 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 2008 | 479 | 0.020 |
Why?
|
| Deoxyadenine Nucleotides | 1 | 2003 | 24 | 0.020 |
Why?
|
| Deoxyguanine Nucleotides | 1 | 2003 | 21 | 0.020 |
Why?
|
| Point Mutation | 1 | 2007 | 769 | 0.010 |
Why?
|
| Thrombosis | 1 | 2010 | 781 | 0.010 |
Why?
|
| Thiazoles | 1 | 2007 | 726 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 8873 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2003 | 684 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 408 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 2007 | 1245 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 1382 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 2330 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2008 | 2358 | 0.010 |
Why?
|
| Biopsy | 1 | 2008 | 3443 | 0.010 |
Why?
|
| Hypertension, Pulmonary | 1 | 2005 | 462 | 0.010 |
Why?
|
| Myocardium | 1 | 2005 | 1313 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 4744 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2003 | 1910 | 0.010 |
Why?
|
| Time Factors | 1 | 2010 | 12926 | 0.010 |
Why?
|
| Lung | 1 | 2007 | 3151 | 0.010 |
Why?
|
| DNA | 1 | 2003 | 2693 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2002 | 1230 | 0.010 |
Why?
|
| Mice | 1 | 2007 | 34495 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 2007 | 11538 | 0.000 |
Why?
|